You only have so many hours in a day and Neuron is here to help you make the most of them! The platform streamlines, automates, and digitizes legal processes so you can spend time where it's needed. https://lnkd.in/gypQsbVT
About us
Wilson Sonsini Goodrich & Rosati is the premier legal advisor to technology, life sciences, and other growth enterprises worldwide. We represent companies at every stage of development, from entrepreneurial start-ups to multibillion-dollar global corporations, as well as the venture firms, private equity firms, and investment banks that finance and advise them. The firm is nationally recognized as a leader in the fields of corporate governance and finance, mergers and acquisitions, private equity, securities litigation, employment law, intellectual property, and antitrust, among many other areas of law. Our distinguished international roster of clients spans a wide variety of industries, including information technology, life sciences, energy and clean technology, social and traditional media, communications, retail, and financial services. WSGR has offices in Austin; Beijing; Boston; Brussels; Hong Kong; London; Los Angeles; New York; Palo Alto; San Diego; San Francisco; Seattle; Shanghai; Washington, D.C.; and Wilmington, DE. Calling all WSGR alum: Stay connected to alumni, colleagues, and friends on our WSGR Alumni Network, featuring exclusive content and other special offers. Through the site, we share information with alumni about career opportunities; programs and events; alumni, legal industry, and business news; and professional development training, among other topics. Whether you're looking to expand your professional network, find an expert in your field, renew old friendships or establish new ones, or give back by becoming a career mentor, this website is the right place for you. Visit the following link to sign up: www.wsgralumni.com Follow us on Twitter: @wilsonsonsini
- Website
-
http://www.wsgr.com
External link for Wilson Sonsini Goodrich & Rosati
- Industry
- Law Practice
- Company size
- 1,001-5,000 employees
- Headquarters
- Palo Alto, CA
- Type
- Privately Held
- Founded
- 1961
- Specialties
- Law Firm, Corporate Law, Litigation, Intellectual Property, Antitrust, Regulatory, Securities Litigation, Privacy, Class Actions, Investigations, Patent Litigation, Mergers and Acquisitions, Governance, Energy, Tax, Venture Capital, Technology Transactions, and Finance
Locations
-
Primary
650 Page Mill Road
Palo Alto, CA 94304-1050, US
Employees at Wilson Sonsini Goodrich & Rosati
Updates
-
A Wilson Sonsini team led by Matt Squires, Robert Terenzi, and Luis Roberto Fortuño recently advised Strider Technologies on their $55 million Series C! Learn more about Strider Technologies, a leading provider of strategic intelligence, and the transaction at: https://lnkd.in/gMxGaqW9
Strider is excited to announce that we have closed our Series C funding at $55 million. The round was led by Pelion Venture Partners, with participation from AVP (AXA Venture Partners) and our existing investor Valor Equity Partners. With this funding, we’ll advance our AI-driven capabilities on our global intelligence platform, expand operations to new geographies in Europe and Asia, and broaden our reach in the public sector. As organizations increasingly find themselves on the frontlines of this new geopolitical battlefield, Strider is poised to meet the moment with unparalleled strategic intelligence. Stay tuned for what’s to come in our next act. To learn more about our Series C fundraise, read our press release: https://lnkd.in/gr9rteru
-
Wilson Sonsini partners Jess Krannich, Maureen Ohlhausen, and Marina Tsatalis recently participated in an In-House Connect webinar to discuss the current state of restrictive covenant law and the FTC’s non-compete ban. If you missed the live discussion, check out The National Law Journal’s coverage for some key takeaways!
Employers Should Narrowly Tailor Noncompetes to Pass Scrutiny, Say Trade-Secrets Attorneys
-
Congratulations to firm client Cellino on recently being awarded $25 million in funding by Advanced Research Projects Agency for Health (ARPA-H) 🎉Cellino has been a Wilson Sonsini client since 2020, and Wilson Sonsini partner Jennifer Fang has been advising Cellino on the award and other related matters.
🚀 Today marks an extraordinary milestone at Cellino! We are thrilled to announce that our team has been awarded up to $25M in funding from the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services (HHS). This funding will drive the development of our ultra-scalable, autonomous, cassette-based advanced biomanufacturing technology for personalized regenerative medicine. Cellino’s NEBULA (NExt-generation Biomanufacturing ULtra-scalable Approach) project is the first project funded by the Scalable Solutions Mission Office under the ARPA-H Open Broad Agency Announcement. With ARPA-H’s support, Cellino will build a cassette-based biomanufacturing technology capable of scaling the production of personalized induced pluripotent stem cells at hospitals nationwide to develop curative medicines for a range of chronic conditions for an increasingly diverse and aging U.S. patient population. We are excited to move closer to making “Your Cells, Your Cure™” a reality for millions of patients. We are thrilled about this opportunity to advance our goal of making patient-specific stem cell-derived therapies available for broad patient audiences. 📄 Read the full release: https://bwnews.pr/4gfrjlb #ARPAH #Biotech #AI #MachineLearning #PersonalizedMedicine #Collaboration #Innovation #RegenerativeMedicine #BiotechBreakthroughs #CellinoBio #YourCellsYourCure #Biomanufacturing
Cellino Awarded $25M in Funding from the Advanced Research Projects Agency for Health (ARPA-H)
businesswire.com
-
Next week, partner Eva F. Yin, PhD, MPH, JD will be participating in Nucleate Seattle’s most recent installment in the Genesis Lecture Series, an engaging panel on Clinical Development Pathways for biotech companies. The panel, which will include Shannon Eubanks (Proprio Visio), Ajoke Sobanjo-ter Meulen, M.D., M.Sc. (AstraZeneca), and Arna Ionescu Stoll (Wavely Diagnostics, Inc.) will discuss how to navigate regulatory processes and how to incorporate them during the development of your product. Learn more: https://lnkd.in/gv6MaQgt
-
In two weeks, partner Andrea Linna will be speaking at the American Bar Association Health Law Section's Healthcare Delivery & Innovation Conference in Chicago, IL. Andrea's panel, "Balanced Innovation: Regulatory Landscape of AI and Digital Health," will discuss the use of AI technologies in digital health and the unique set of legal challenges it presents. The presentation aims to explore these challenges, focusing on privacy concerns, regulatory compliance, liability issues, and the ethics of AI decision-making in healthcare. Learn more: https://lnkd.in/gK-a4bj5
-
A Wilson Sonsini team led by Jason Skolnik and Brandon Shaw recently advised SpectraWAVE, Inc., a medical imaging company focused on improving the treatment and outcomes for patients with coronary artery disease (CAD), on their $50 million Series B funding round! Learn more about the transaction and full team involved at: https://lnkd.in/gs2caV77
We’re thrilled to announce a successful $50M Series B financing led by Johnson and Johnson Innovation – JJDC, Inc. and joined by a number of leading MedTech investors including S3 Ventures, Lumira Ventures, SV Health Investors, and Deerfield Management. This new funding will support commercial expansion of our AI enabled FDA-cleared intravascular imaging solution, the HyperVue Imaging System, as well as our in-development wire-free physiology technology. This funding comes at a pivotal time in the imaging space as evidence continues to grow and recently released European guidelines now cite intravascular imaging as a 1A recommendation for supporting PCI of complex lesions. We’re excited about what’s next. Big things are on the horizon for SpectraWAVE and coronary care! Learn more here: https://lnkd.in/edtWFzyn #ImageFirst
-
Next week, partner Myra Sutanto Shen will join Lorman Education Services for a webinar that will help tax advisors and in-house tax practitioners understand the reasons when to pursue a tax-free spin-off, the requirements of a tax-free spin-off and common pitfalls in tax-free spinoff structuring. Learn more and register for the live webinar "The Use of Spinoffs: Tax Strategies to Dispose of Corporate Assets," at: https://lnkd.in/ggseriGd
-
Meet our Colorado-based #lifesciences team! To learn more about our team and the life sciences work we do in Colorado, feel free to connect with our key contacts: Tony Jeffries, Vern Norviel, Brent Fassett, Bill Barrett, David Strong, Jesse Schumaker, Sara P., and Matthew Julian Meyer.
-
As U.S.-based venture capital funds have become an increasingly significant source of capital for UK start-up and scale-up companies, the negotiation of terms often give rise to gaps in expectations and market norms between the two jurisdictions. In the first article of our Transatlantic Venture Series, authors Michael Labriola, Diviya Padman, and Conor Cannon dive into the major differences in venture capital practices in the U.K. and the U.S. While there are similarities, this article highlights the top differences in structure, process, and terms between a U.S. and U.K.-style venture/growth capital deal. Read it in full at: https://lnkd.in/g3bgZyaY